RecruitingPhase 3NCT06430125
Nephroprotective Effect of Nicorandil in Type 2 Diabetes Mellitus
Clinical Study Evaluating the Nephroprotective Effect of Nicorandil in Patients With Type 2 Diabetes Mellitus
Sponsor
Tanta University
Enrollment
46 participants
Start Date
Feb 28, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study aims to evaluate the possible nephroprotective effect of nicorandil in patients with type 2 diabetes mellitus .
Eligibility
Min Age: 18 YearsMax Age: 60 Years
Inclusion Criteria5
- Patients newly diagnosed with T2DM with diet control and good glycemic index ( Hb A1C\< 7 )
- Age range between 18 and 60 years old.
- Both sexes.
- Stage 1and Stage 2 CKD according to KDIGO .
- Controlled HTN .
Exclusion Criteria5
- Pregnant and lactating females.
- Patients with hypersensitivity to nicorandil.
- Other Causes of CKD or Nephropathy eg : Uncontrolled HTN , Renal Malignancy , collagen disease as Amyloidosis and some autoimmune disease as ( SLE and Rh.fever ) .
- Uncontrolled HTN and its antihypertensive medications ( ACEI , ARB ) and other antihypertensive medications .
- Patients receiving nephrotoxic drugs as aminoglycosides, non-steroidal anti inflammatory drugs and contrast media.
Interventions
DRUGNicorandil 10 MG Oral Tablet
Nicorandil 10 MG oral tablet twice daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06430125